Effects of verbascoside biotechnologically produced by Syringa vulgaris plant cell cultures in a rodent model of colitis.
The aim of the present study was to examine the effects of verbascoside (VB) in rats subjected to experimental colitis. Colitis was induced in rats by intracolonic instillation of 2,4 dinitrobenzene sulfonic acid (DNBS; 25 mg/rat). VB was administered daily per os (0.2 and 2 mg/kg) 4 days after DNBS administration in the colon. Treatment with VB significantly (P < 0.01) reduced macroscopic damage score, loss of body weight, myeloperoxidase activity and thiobarbituric acid-reactant substances. Moreover, the intensity of the positive staining for tumor necrosis factor-alpha, interleukin-1beta, intercellular adhesion molecule-1, P-selectin, inducible nitric oxide synthase, and poly(ADP ribose) was also significantly (P < 0.01) reduced by VB treatment. Therefore, VB treatment significantly (P < 0.01) reduced the degree of NF-kappaB p65 and activation of the pro-active form metalloproteinase (MMP)-2 and pro-MMP-9 activity. The results of this study suggested that VB functions as an intracellular radical scavenger and so reduces the microscopic and macroscopic signs of colitis in the rat. Therefore, administration of VB may be beneficial for the treatment of inflammatory bowel disease.
Mazzon
Emanuela
E
IRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy.
Esposito
Emanuela
E
Di Paola
Rosanna
R
Riccardi
Luisa
L
Caminiti
Rocco
R
Dal Toso
Roberto
R
Pressi
Giovanna
G
Cuzzocrea
Salvatore
S
D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D002478:Cells, Cultured; D003092:Colitis / Q000188:drug therapy* / Q000503:physiopathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004792:Enzyme Precursors / Q000187:drug effects / Q000378:metabolism; D018093:Gelatinases / Q000187:drug effects / Q000378:metabolism; D005960:Glucosides / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000187:drug effects / Q000378:metabolism; D009195:Peroxidase / Q000187:drug effects / Q000378:metabolism; D010636:Phenols / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D031662:Syringa / Q000737:chemistry*; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D051996:Transcription Factor RelA / Q000187:drug effects / Q000378:metabolism; D059808:Polyphenols
D000975:Antioxidants; D004792:Enzyme Precursors; D018093:Gelatinases; D005960:Glucosides; D020780:Matrix Metalloproteinase 9; D009195:Peroxidase; D010636:Phenols; D017392:Thiobarbituric Acid Reactive Substances; D051996:Transcription Factor RelA; C058956:acteoside; D059808:Polyphenols; C120487:pro-matrix metalloproteinase 9; C069860:progelatinase